1,043 reports of this reaction
2.1% of all IBUPROFEN AND DIPHENHYDRAMINE CITRATE reports
#9 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #9 most commonly reported adverse reaction for IBUPROFEN AND DIPHENHYDRAMINE CITRATE, manufactured by Kenvue Brands LLC. There are 1,043 FDA adverse event reports linking IBUPROFEN AND DIPHENHYDRAMINE CITRATE to DRUG HYPERSENSITIVITY. This represents approximately 2.1% of all 50,486 adverse event reports for this drug.
Patients taking IBUPROFEN AND DIPHENHYDRAMINE CITRATE who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for IBUPROFEN AND DIPHENHYDRAMINE CITRATE, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for IBUPROFEN AND DIPHENHYDRAMINE CITRATE:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 1,043 FDA reports for IBUPROFEN AND DIPHENHYDRAMINE CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 2.1% of all adverse event reports for IBUPROFEN AND DIPHENHYDRAMINE CITRATE, making it a notable side effect.
If you experience drug hypersensitivity while taking IBUPROFEN AND DIPHENHYDRAMINE CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.